With the continued growth of the life sciences sector in Asia, companies are increasingly entering into licensing and collaboration arrangements to drive innovation and manage risk.

Understanding the risks involved in licensing and collaboration agreements is crucial for companies looking to tap into the thriving Asian market and establish successful partnerships. In this episode of our two-part series focusing on life sciences, podcast host Ninette Dodoo is joined by Kristen Riemenschneider, Mary Lehner, Richard Bird, and Xin Liu to discuss the complex regulatory landscape associated with licensing and collaboration arrangements. This includes anti-bribery, sanctions and export control risks, unique IP ownership challenges, data sharing issues and antitrust considerations concerns, which can make or break these deals.